A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...
BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
Statin use linked to better survival but higher cardiac adverse events in advanced prostate cancer patients treated with ...
A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.
Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...
Combining 177 Lu-PSMA-617 with SOC produced statistically significant rPFS, reducing the risk of radiographic progression or death by 28% (HR 0.72; 95% CI, 0.58-0.90) vs SOC alone in patients with ...
Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...
Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback